Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 1, Pages e86667
Publisher
Public Library of Science (PLoS)
Online
2014-02-01
DOI
10.1371/journal.pone.0086667
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases
- (2013) Satoko Matsueda et al. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY
- A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer
- (2010) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines
- (2010) Tetsuro Sasada et al. EUROPEAN JOURNAL OF CANCER
- Gene-expression profiling in vaccine therapy and immunotherapy for cancer
- (2010) Davide Bedognetti et al. Expert Review of Vaccines
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation
- (2010) Michael X. Pham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation
- (2009) A. Talavera et al. CANCER RESEARCH
- Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
- (2009) Marianna Sabatino et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival
- (2009) D. Bogunovic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
- (2008) Judith Schmiedel et al. CANCER CELL
- The ErbB kinase domain: Structural perspectives into kinase activation and inhibition
- (2008) Ron Bose et al. EXPERIMENTAL CELL RESEARCH
- Ligand-induced ErbB receptor dimerization
- (2008) Mark A. Lemmon EXPERIMENTAL CELL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation